← Back to guidelines
Cardiology24 papers

Malignant neoplasm of spinal cord, intramedullary

Last edited: 4/22/2026

Overview

Malignant neoplasms of the intramedullary spinal cord are rare and aggressive tumors that arise within the spinal cord itself, often leading to significant neurological deficits due to their location and invasive nature. 13

Diagnosis

  • Imaging: MRI is essential, with post-gadolinium imaging often revealing specific signs like "rim" and "flame" enhancement patterns indicative of metastases 2.
  • Neurological Assessment: Perioperative evaluation using scores like surgical or spinal cord injury scales is crucial 1.
  • Histopathological Confirmation: Required for definitive diagnosis, distinguishing between primary and metastatic lesions 23.
  • Management

  • Surgical Intervention: Microsurgery aimed at maximal tumor resection with intraoperative neurophysiological monitoring to minimize neurological morbidity 1.
  • Syringomyelia Management: Presence of syringomyelia often indicates better resectability and may correlate with quicker postoperative recovery, though it does not significantly affect long-term prognosis 4.
  • Postoperative Monitoring: Regular follow-up MRI and neurological assessments to monitor recurrence and functional outcomes 13.
  • Special Populations

  • Pediatrics: Quality of life significantly impacts postoperative outcomes; multidimensional quality of life assessments like the PedsQL 4.0 are recommended for follow-up 1.
  • Comorbidities: No specific recommendations provided for elderly or comorbid conditions in the abstracts; focus remains on preoperative neurological status and surgical approach 4.
  • Key Recommendations

  • Utilize microsurgical resection with intraoperative neurophysiological monitoring to optimize neurological outcomes in intramedullary spinal cord tumors (Evidence: Moderate 1).
  • Incorporate multidimensional quality of life assessments, such as the PedsQL 4.0, in pediatric patients post-surgery to evaluate long-term impact (Evidence: Moderate 1).
  • Consider the presence of syringomyelia as a marker for potentially better resectability and quicker postoperative recovery, though it does not alter long-term prognosis significantly (Evidence: Moderate 4).
  • References

    1 Schneider C, Hidalgo ET, Schmitt-Mechelke T, Kothbauer KF. Quality of life after surgical treatment of primary intramedullary spinal cord tumors in children. Journal of neurosurgery. Pediatrics 2014. link 2 Rykken JB, Diehn FE, Hunt CH, Eckel LJ, Schwartz KM, Kaufmann TJ et al.. Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases. AJNR. American journal of neuroradiology 2013. link 3 Cornips EM, Vinken PA, Ter Laak-Poort M, Beuls EA, Weber J, Vles JS. Intramedullary cavernoma presenting with hematomyelia: report of two girls. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2010. link 4 Samii M, Klekamp J. Surgical results of 100 intramedullary tumors in relation to accompanying syringomyelia. Neurosurgery 1994. link

    Original source

    1. [1]
      Quality of life after surgical treatment of primary intramedullary spinal cord tumors in children.Schneider C, Hidalgo ET, Schmitt-Mechelke T, Kothbauer KF Journal of neurosurgery. Pediatrics (2014)
    2. [2]
      Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases.Rykken JB, Diehn FE, Hunt CH, Eckel LJ, Schwartz KM, Kaufmann TJ et al. AJNR. American journal of neuroradiology (2013)
    3. [3]
      Intramedullary cavernoma presenting with hematomyelia: report of two girls.Cornips EM, Vinken PA, Ter Laak-Poort M, Beuls EA, Weber J, Vles JS Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2010)
    4. [4]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG